News Releases
All Releases
View Summary Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer
Apr 9, 2014
PDF 22.7 KB Add to Briefcase
View Summary Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer
Apr 7, 2014
PDF 19.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting
Apr 1, 2014
PDF 16.0 KB Add to Briefcase
View Summary Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase l/ll Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer
Mar 14, 2014
PDF 18.2 KB Add to Briefcase
View Summary Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies
Mar 13, 2014
PDF 56.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Mar 11, 2014
PDF 13.1 KB Add to Briefcase
View Summary Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Mar 11, 2014
PDF 20.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments
Mar 7, 2014
PDF 31.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences
Mar 4, 2014
PDF 16.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014
Feb 27, 2014
PDF 13.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering
Feb 27, 2014
PDF 16.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Upcoming Events
Feb 19, 2014
PDF 14.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Closing of Preferred Stock Offering
Feb 19, 2014
PDF 16.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred Stock
Feb 11, 2014
PDF 17.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Public Offering of Series E Preferred Stock
Feb 5, 2014
PDF 16.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer
Jan 6, 2014
PDF 18.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Dec 30, 2013
PDF 19.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments
Dec 10, 2013
PDF 34.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Upcoming Events
Nov 26, 2013
PDF 13.7 KB Add to Briefcase
View Summary Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies
Nov 8, 2013
PDF 21.6 KB Add to Briefcase
Showing 1-20 of 536 Page: 1 2 3 4 5 ... 27  Next 20
Add to Briefcase = add release to Briefcase
Print E-mail